Mitotane use in inoperable adrenal cortical carcinoma.
D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy*; D000328:Adult; D003930:Diabetic Retinopathy / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009468:Neuromuscular Diseases / Q000139:chemically induced; D012075:Remission, Spontaneous; D012871:Skin Diseases / Q000139:chemically induced; D013256:Steroids / Q000652:urine; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D013256:Steroids; D008939:Mitotane